- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05458856
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate (TriptoSwitch)
An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 6-month Formulation Administered Subcutaneously in Participants With Locally Advanced and/or Metastatic Prostate Cancer Previously Treated and Castrated With a GnRH Analogue
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium
- Cliniques Universitaires Saint-Luc
-
Edegem, Belgium
- UZ Antwerpen
-
Kortrijk, Belgium, 8500
- AZGroeninge
-
-
-
-
-
Brno, Czechia
- Fakultni nemocnice u sv. Anny v Brne
-
Olomouc, Czechia
- Fakultní Nemocnice Olomouc
-
Praha, Czechia
- Vseobecna fakultni nemocnice v Praze
-
-
-
-
-
Angers, France, 49933
- Centre Hospitalier Universitaire D'Angers - Urologie
-
Brest, France, 29200
- CHU Brest-Hopital Morvan Institut de Cancerologie et d'Hemat
-
Brest, France, 29229
- Clinique Pasteur-Lanroze - Oncology
-
La Chaussée-Saint-Victor, France, 41260
- Polyclinique de Blois - Service oncologie
-
Lille, France, 59000
- Hopital Privé Métropole Lille - Polyclinique Du Bois
-
Lyon, France, 69437
- CHU Hopital Edouard Herriot
-
Paris, France, 75018
- Hopital Bichat
-
Paris, France, 75014
- L'Institut Mutualiste Montsouris
-
Pierre-Bénite, France, 69495
- Centre Hospitalier Lyon Sud
-
Suresnes, France, 92151
- Hopital Foch - Urologie et Transplantation Ré
-
Toulouse, France, 31400
- Saint Jean Languedoc and La Croix du Sud Hospital
-
-
-
-
-
Dresden, Germany, 01307
- Universitätsklinikum Carl Gustav Carus
-
Jena, Germany
- University Hospital Jena KöR
-
Muenster, Germany, 48149
- Universitaetsklinikum Muenster
-
Nürtingen, Germany, 72622
- Studienpraxis Urologie
-
Tuebingen, Germany
- Universität Tuebingen - Urology
-
-
-
-
-
Kaunas, Lithuania
- Hospital of Lithuanian University of Health Sciences Kaunas
-
Klaipėda, Lithuania, LT92288
- Klaipeda university hospital
-
Vilnius, Lithuania, LT-08660
- National Cancer Institute
-
Vilnius, Lithuania
- Vilniaus Universiteto ligonines Santariskiu Klinikos
-
-
-
-
-
Amsterdam, Netherlands
- The Netherlands Cancer Institute - Oncology
-
Den Haag, Netherlands
- Haga Ziekenhuis
-
Eindhoven, Netherlands, 5623 EJ
- Catharina Ziekenhuis - Urology
-
Nijmegen, Netherlands, 6532 SZ
- CWZ
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spain, 08041
- Hospital de La Santa Creu i Sant Pau - Oncología Médica
-
Bilbao, Spain, 48013
- H. de Basurto - Urología
-
Lugo, Spain, 27004
- POLUSA - Policlínico Lucense - Oncología
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre- Urology
-
Oviedo, Spain, 33011
- Hospital Universitario Central de Asturias (HUCA)
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocio- Urología Pediátrica
-
Valencia, Spain, 46026
- Hospital Universitari i Politècnic La Fe
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria :
- Participant is male and must be 18 years of age inclusive, at the time of signing the informed consent
- Participant has histologically or cytologically proven prostate cancer with rising PSA after failed local therapy or metastatic disease, or requiring radiotherapy, and be a candidate for long-term (i.e. >1 year) androgen deprivation therapy
- Participant requires a GnRH analogue treatment for a minimum of 18 months, of which a minimum of 3 months of GnRH analogue treatment has already been provided prior to screening. (Note: participants must receive study intervention on Day 1 in accordance with the treatment schedule of their previously received GnRH analogue therapy).
- Has serum testosterone levels <1.735 nmol/L (50 ng/dL) at screening
- Has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1
- Has a life expectancy of >18 months
- Male participants must agree that, if their partner is at risk of becoming pregnant (although highly unlikely in this study population), they will use an effective method of contraception. The participant must agree to use the contraception during the whole of the study and for 9 months after the last dose of study intervention
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Exclusion Criteria :
- Presence of another neoplastic lesion or brain metastases
- Metastatic hormone-sensitive prostate cancer with high tumour burden
- Metastatic castration-resistant prostate cancer
- Any concomitant disorder or resulting therapy that is likely to interfere with participant compliance or with the study in the opinion of the investigator
- Use of finasteride (Proscar®) or dutasteride (Avodart®/Avolve®) within the past 6 months
- Planned intermittent scheme of GnRH analogue
- At the time of screening, planned use of any chemotherapy for prostate cancer during the study
- Prior hypophysectomy or adrenalectomy
- Participation in another study with an experimental drug within 3 months before signing informed consent or within five half-lives of the investigational drug (whichever was the longer), or any other type of medical research
- Severe kidney or liver failure (creatinine >2 times the normal range, aspartate aminotransferase and alanine aminotransferase >3 times the normal range)
- Any concomitant disorder or resulting therapy that is likely to interfere with participant's compliance, the subcutaneous administration of the drug or with the study in the opinion of the investigator
- Previous history of QT prolongation or concomitant use of medicinal products known to prolong the QT interval or with a known risk of torsades de pointes
- Known hypersensitivity to triptorelin or any of its excipients, GnRH, other GnRH agonist/analogues
- Known active use of recreational drug or alcohol dependence in the opinion of the investigator
- Inability to give informed consent or to comply fully with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Triptorelin embonate
All participants will receive triptorelin embonate 22.5 mg
|
A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants maintaining castrate levels of serum testosterone
Time Frame: At day 29
|
The percentage of participants remaining castrated (maintenance of castration defined as testosterone <1.735 nmol/L (50 ng/dL) at Day 29, Day 85, Day 141, Day 169, Day 253, Day 309 and Day 337) during the study.
|
At day 29
|
Percentage of participants maintaining castrate levels of serum testosterone
Time Frame: At day 85
|
The percentage of participants remaining castrated (maintenance of castration defined as testosterone <1.735 nmol/L (50 ng/dL) at Day 29, Day 85, Day 141, Day 169, Day 253, Day 309 and Day 337) during the study.
|
At day 85
|
Percentage of participants maintaining castrate levels of serum testosterone
Time Frame: At day 141
|
The percentage of participants remaining castrated (maintenance of castration defined as testosterone <1.735 nmol/L (50 ng/dL) at Day 29, Day 85, Day 141, Day 169, Day 253, Day 309 and Day 337) during the study.
|
At day 141
|
Percentage of participants maintaining castrate levels of serum testosterone
Time Frame: At day 169
|
The percentage of participants remaining castrated (maintenance of castration defined as testosterone <1.735 nmol/L (50 ng/dL) at Day 29, Day 85, Day 141, Day 169, Day 253, Day 309 and Day 337) during the study.
|
At day 169
|
Percentage of participants maintaining castrate levels of serum testosterone
Time Frame: At day 253
|
The percentage of participants remaining castrated (maintenance of castration defined as testosterone <1.735 nmol/L (50 ng/dL) at Day 29, Day 85, Day 141, Day 169, Day 253, Day 309 and Day 337) during the study.
|
At day 253
|
Percentage of participants maintaining castrate levels of serum testosterone
Time Frame: At day 309
|
The percentage of participants remaining castrated (maintenance of castration defined as testosterone <1.735 nmol/L (50 ng/dL) at Day 29, Day 85, Day 141, Day 169, Day 253, Day 309 and Day 337) during the study.
|
At day 309
|
Percentage of participants maintaining castrate levels of serum testosterone
Time Frame: At day 337
|
The percentage of participants remaining castrated (maintenance of castration defined as testosterone <1.735 nmol/L (50 ng/dL) at Day 29, Day 85, Day 141, Day 169, Day 253, Day 309 and Day 337) during the study.
|
At day 337
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants castrated
Time Frame: Day 29, Day 85, Day 141, Day 169, Day 253, Day 309, Day 337
|
Serum will be analysed to determine concentrations of testosterone using a validated, specific and sensitive liquid chromatography tandem mass spectrometry methods Castration defined as testosterone <1.735 nmol/L (50 ng/dL)).
|
Day 29, Day 85, Day 141, Day 169, Day 253, Day 309, Day 337
|
Percentage of participants with a serum testosterone level <0.694 nmol/L (20 ng/dL)
Time Frame: From baseline to Week 52
|
From baseline to Week 52
|
|
Percentage of participants with a serum testosterone level <0.69 nmol/L (20 ng/dL)
Time Frame: Day 29, Day 85, Day 141, Day 169, Day 253, Day 309, Day 337
|
Day 29, Day 85, Day 141, Day 169, Day 253, Day 309, Day 337
|
|
Percentage of participants castrated
Time Frame: Day 3 and Day 7 after each injection administered on Day 1 and Day 169
|
Serum will be analysed to determine concentrations of testosterone using a validated, specific and sensitive liquid chromatography tandem mass spectrometry methods.
Castration defined as testosterone <1.735 nmol/L (50 ng/dL)).
|
Day 3 and Day 7 after each injection administered on Day 1 and Day 169
|
Percent change in Prostate Specific Antigen
Time Frame: Baseline, Day 169 and Day 337
|
Defined as the absolute value of difference between the PSA values at each timepoint and the baseline value divided by the baseline value.
Blood samples will be analysed to determine concentrations of PSA.
|
Baseline, Day 169 and Day 337
|
Incidence of treatment-emergent adverse events (including local tolerability)
Time Frame: Up to Day 337
|
All adverse events and serious adverse events will be collected from the signing of the informed consent form until the end of the study.
|
Up to Day 337
|
Change in clinical safety laboratory blood chemistry parameters
Time Frame: Baseline and Day 337
|
Number of abnormal laboratory parameters (creatinine, glucose, ALT, AST, alkaline phosphatase, total and conjugated bilirubin) or other safety assessments, including those that worsen from baseline and if clinically significant by investigator's judgment.
|
Baseline and Day 337
|
Change in clinical safety laboratory haematology parameters
Time Frame: Baseline and Day 337
|
Number of abnormal laboratory parameters (WBC and differential count, platelet count, Hb) or other safety assessments, including those that worsen from baseline and if clinically significant by investigator's judgment.
|
Baseline and Day 337
|
Change in physical examination
Time Frame: Baseline, Day 169, and Day 337
|
Number of abnormal physical examination (cardiovascular, respiratory, gastrointestinal and neurological systems, Height and weight) including those that worsen from baseline and if clinically significant by investigator's judgment.
|
Baseline, Day 169, and Day 337
|
Change in electrocardiogram (ECG)
Time Frame: Baseline and Day 337
|
A single 12-lead ECG will be recorded so that the different ECG intervals (RR, PR, QRS, QT, QTcF) can be measured automatically.
The ECG will be recorded with the participant in supine position after five minutes of rest until four regular consecutive complexes are available.
|
Baseline and Day 337
|
Change in heart rate
Time Frame: Baseline and at each visit up to Day 337
|
Heart rate will be assessed with an automated device so that measurements are independent of the observer.
Heart rate will be recorded after 5 minutes rest in supine position.
Absolute values and change from Baseline will be analysed.
|
Baseline and at each visit up to Day 337
|
Change in blood pressure
Time Frame: Baseline and at each visit up to Day 337
|
Blood pressure will be assessed with an automated device so that measurements are independent of the observer.
Blood pressure will be recorded after 5 minutes rest in supine position.
Absolute values and change from Baseline will be analysed.
|
Baseline and at each visit up to Day 337
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ipsen Medical Director, Ipsen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Luteolytic Agents
- Triptorelin Pamoate
Other Study ID Numbers
- D-FR-52014-245
- 2021-005719-29 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Triptorelin embonate 22.5 mg
-
Debiopharm International SAQuintiles, Inc.Completed
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Not yet recruitingObesity | Overweight
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Not yet recruiting
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Recruiting
-
AstraZenecaCompletedProstatic Neoplasms | Metastases, NeoplasmUnited States
-
Cancer Research AntwerpBayer; Veracyte, Inc.Recruiting
-
IpsenActive, not recruitingMetastatic Prostate Cancer | Advanced Prostate Cancer | Locally Advanced Prostate CancerChina
-
Debiopharm International SACompletedProstatic NeoplasmSouth Africa
-
Marco Lorenzo BonuAzienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaRecruiting